@article{95399cb1d53548ebb3619f766cac596d,
title = "An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma",
abstract = "Dysregulated metabolism is a hallmark of cancer, manifested through alterations in metabolites. We performed metabolomic profiling on 138 matched clear cell renal cell carcinoma (ccRCC)/normal tissue pairs and found that ccRCC is characterized by broad shifts in central carbon metabolism, one-carbon metabolism, and antioxidant response. Tumor progression and metastasis were associated with metabolite increases in glutathione and cysteine/methionine metabolism pathways. We develop an analytic pipeline and visualization tool (metabolograms) to bridge the gap between TCGA transcriptomic profiling and our metabolomic data, which enables us to assemble an integrated pathway-level metabolic atlas and to demonstrate discordance between transcriptome and metabolome. Lastly, expression profiling was performed on a high-glutathione cluster, which corresponds to a poor-survival subgroup in the ccRCC TCGA cohort. Using metabolomic profiling, Ari Hakimi et al. show that clear cell renal cell carcinoma is characterized by broad shifts in central carbon metabolism, one-carbon metabolism, and antioxidant response. They also develop metabolograms to allow integrating the TCGA transcriptomic data with their metabolomic data.",
author = "Hakimi, {A. Ari} and Ed Reznik and Lee, {Chung Han} and Creighton, {Chad J.} and Brannon, {A. Rose} and Augustin Luna and Aksoy, {B. Arman} and Liu, {Eric Minwei} and Ronglai Shen and William Lee and Yang Chen and Stirdivant, {Steve M.} and Paul Russo and Chen, {Ying Bei} and Tickoo, {Satish K.} and Reuter, {Victor E.} and Cheng, {Emily H.} and Chris Sander and Hsieh, {James J.}",
note = "Funding Information: We thank our patients for donating their tumors and the team members of the MSK TKCRP for the advancement of kidney cancer research. We also thank Drs. Craig B. Thompson and Lydia Finley for their critical comments on the manuscript. A.A.H. and P.R. were supported by the Sidney Kimmel Center for Prostate and Urologic Cancers and by the MSK Cancer Center Support Grant/Core Grant (P30 CA008748). C.J.C. was supported by the NIH P30 CA125123 and 5U24CA143843. A.R.B. was supported by the NCI 5T32CA160001. C.S. was supported by the MSK Center for Translational Cancer Genomic Analysis and U24 CA143840. J.J.H. was supported by The Jill and Jeffrey Weiss Fund to the Cure of Kidney Cancer and J. Randall & Kathleen L. MacDonald Kidney Cancer Research Fund. Yang Chen was and Steve M Stirdivant is an employee at Metabolon. Funding Information: We thank our patients for donating their tumors and the team members of the MSK TKCRP for the advancement of kidney cancer research. We also thank Drs. Craig B. Thompson and Lydia Finley for their critical comments on the manuscript. A.A.H. and P.R. were supported by the Sidney Kimmel Center for Prostate and Urologic Cancers and by the MSK Cancer Center Support Grant/Core Grant ( P30 CA008748 ). C.J.C. was supported by the NIH P30 CA125123 and 5U24CA143843 . A.R.B. was supported by the NCI 5T32CA160001 . C.S. was supported by the MSK Center for Translational Cancer Genomic Analysis and U24 CA143840. J.J.H. was supported by The Jill and Jeffrey Weiss Fund to the Cure of Kidney Cancer and J. Randall & Kathleen L. MacDonald Kidney Cancer Research Fund. Yang Chen was and Steve M Stirdivant is an employee at Metabolon. Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",
year = "2016",
month = jan,
day = "11",
doi = "10.1016/j.ccell.2015.12.004",
language = "English",
volume = "29",
pages = "104--116",
journal = "Cancer Cell",
issn = "1535-6108",
number = "1",
}